Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

RNA-seq of Myeloproliferative neoplasms primary CD34+ HSPCs and cell lines after tamoxifen treatment

ABSTRACT: RNA-seq of Myeloproliferative neoplasms primary CD34+ HSPCs and cell lines after tamoxifen treatment

PROVIDER: PRJNA721714 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR14231902_1.fastq.gz	Fastqsanger.gz
	SRR14231902_2.fastq.gz	Fastqsanger.gz
	SRR14231903_1.fastq.gz	Fastqsanger.gz
	SRR14231903_2.fastq.gz	Fastqsanger.gz
	SRR14231904_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 72

Similar Datasets

Bulk RNAseq of primary CD34+ HSPCs in Myeloproliferative neoplasms patients receiving tamoxifen

Project description:Bulk RNAseq of primary CD34+ HSPCs in Myeloproliferative neoplasms patients receiving tamoxifen

| PRJNA721718 | ENA

Bulk RNAseq of primary CD34+ HSPCs in Myeloproliferative neoplasms patients receiving tamoxifen

Project description:TAMARIN study is a Phase II, multicenter, single arm A’herns design clinical trial assessing tamoxifen’s safety and activity in reducing molecular markers of disease burden in MPN.The primary outcome (≥50% allele burden reduction at 24 weeks) was met by 3/37 patients; 5/37 additional patients showed ≥25% reductions. CD34+ HSPCs were collected from responders and non-respondersin the baseline line and 24W after tamoxifen treatment. RNAseq was performed to investigate the molecular signature about tamoxifen sensitivity and pharmacological mechanism of tamoxifen in MPN patients.

2023-10-02 | GSE172022 | GEO

Myelodysplastic/myeloproliferative neoplasms

Project description:This SuperSeries is composed of the following subset Series: GSE21948: High Density custom Agilent 44K CGH array analysis of 7q and TET2 region in myelodysplastic/myeloproliferative neoplasms GSE21990: Affymetrix SNP 6.0 array data for myelodysplastic/myeloproliferative neoplasms Refer to individual Series

2010-06-30 | E-GEOD-21991 | biostudies-arrayexpress

Pathophysiology of arterial cardiovascular events in patients with JAK2V617F myeloproliferative neoplasms

Project description:Cardiovascular events are the leading cause of death in patients with JAK2V617F myeloproliferative neoplasms. Their mechanisms are poorly understood. To investigate the role of microvesicles in these events, we performed a proteomic analysis of microvesicles derived from red blood cells from mice with a myeloproliferative neoplasms (Jak2V617F Flex/WT ;VE-cadherin-Cre) vs. littermate controls.

2020-02-17 | PXD014451 | Pride

Comprehensive profiing of clinical JAK inhibitors in myeloproliferative neoplasms

Project description:Comprehensive profiing of clinical JAK inhibitors in myeloproliferative neoplasms

2023-05-24 | GSE229712 | GEO

Genetic charcterization of myeloproliferative neoplasms (MPN)

Project description:Genetic charcterization of myeloproliferative neoplasms (MPN)

| PRJNA1162027 | ENA

Mesenchymal stromal cells from JAK2V617F myeloproliferative neoplasms support healthy and malignant haematopoiesis in a humanised scaffold model in vivo

Project description:Myeloproliferative Neoplasms (MPN) are malignancies of hematopoietic stem and progenitor cells (HSPCs) that lead to the overproduction of mature blood cells. These disorders include Essential Thrombocythemia (ET), Polycythaemia Vera (PV), and Primary Myelofibrosis (PMF), primarily driven by somatic mutations such as JAK2V617F. Research indicates that mesenchymal stromal cells (MSCs) support fibrosis in PMF, though their role in ET and PV remains less clear. Furthermore, in vivo studies of ET/PV HSPCs remain a challenge due to low engraftment levels in xenograft models.

2025-08-27 | GSE288706 | GEO

Targeting the CALR Interactome in Myeloproliferative Neoplasms

Project description:Targeting the CALR Interactome in Myeloproliferative Neoplasms

| PRJNA491714 | ENA

JAK2V617F Impairs Lymphoid Differentiation in Myeloproliferative Neoplasms

Project description:JAK2V617F Impairs Lymphoid Differentiation in Myeloproliferative Neoplasms

| PRJNA1122535 | ENA

Genetic variation at MECOM, TERT, JAK2 and HBS1L-MYB predispose to myeloproliferative neoplasms

Project description:Genome-wide association study of JAK2 V617F negative myeloproliferative neoplasms consisting of 524 cases at stage 1

2015-02-20 | E-MTAB-3340 | biostudies-arrayexpress